Pfizer to broaden RSV portfolio with deal to acquire ReViral for up to $525 million

  • In a bid a strengthen its portfolio targeted at respiratory syncytial virus (RSV), Pfizer (NYSE:PFE) has agreed to acquire privately-held ReViral for a total consideration of up to $525 million, including upfront and development milestones.
  • ReViral has clinical candidates targeted at RSV infection, including sisunatovir, an oral inhibitor to block viral fusion to host cells.
  • Backed by Fast Track designation by the U.S. Food and Drug Administration (FDA), sisunatovir is currently undergoing Phase 2 studies in infants following a phase 2 RSV human challenge study in healthy adults.
  • The programs, being advanced by ReViral, are expected to generate more than $1.5 billion of annual revenue if successful, according to Pfizer (PFE).
  • 'The proposed acquisition of ReViral's pipeline of therapeutic candidates is complementary to our efforts to advance the first vaccine candidate to help protect against this harmful disease," said Annaliesa Anderson, a Senior Vice President at the company.

    For this year the company, located in New York City revenue will be around 105.44 billion USD. This is according to the average of the analysts' estimates. The expected revenue would be a record for the company. This is rather significant more than 2021's revenue of 81.29 billion USD.

    Historical revenues and results Pfizer plus estimates 2022

    aandelenanalyse

    The analysts expect for 2022 a net profit of 39.47 billion USD. For this year the consensus of the result per share is a profit of 6.86 USD. So the price/earnings-ratio equals 7.24.

    Huge dividend Pfizer

    Per share the analysts anticipate on a dividend of 1.65 USD per share. The dividend yield is then 3.32 percent. The average dividend yield of the pharmaceutical companies is a limited 1.37 percent.

    Most recent target prices around 53 USD

    The most recent recommendations for the pharmaceutical company are from JP Morgan, Barclays and UBS .

    Pfizer 's market capitalization is around 276.46 billion USD. 29

    On Wednesday the stock closed at 49.66 USD.

    Historical stock prices Pfizer

    stock analysis pfizer

    ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
    news@valuespectrum.com

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.

    • Other stock news
    Pfizer CEO Bourla says company prepared if modified COVID vaccine required
    Pfizer now in top highest dividend yields in America
    Analysts expect revenue increase Pfizer, quite high dividend
    DoD awards Pfizer $1.4B contract modification for 200M COVID vaccine doses for donation
    Pfizer awarded $3.5 billion contract by U.S. Army to produce COVID-19 vaccines
    Pfizer to begin clinical trials for a COVID-19 shot targeting Delta variant
    India in discussions with Pfizer to obtain 50M doses of COVID-19 vaccine
    Sector news
    Analysts anticipate for 2024 on revenue increase Astrazeneca, high dividend yield
    High dividend yield Sanofi-Aventis
    Sanofi-Aventis in top French dividend returns
    Novartis among highest Swiss dividend stocks
    Analysts expect over 2023 revenue increase UCB
    Pfizer CEO Bourla says company prepared if modified COVID vaccine required
    Analysts: this year best year ever for Carl Zeiss Meditec
    National news
    NXP reaps benefits from FRAMOS collaboration
    Tesla net onder de 500.000 cars per year
    Analysts expect over 2024 revenue decrease Caterpillar
    Analysts expect sales decline Biogen
    Analysts anticipate for 2024 on revenue increase Cognizant
    Analysts expect over 2024 growing sales Colgate-Palmolive
    Analysts expect over 2024 revenue expansion Patterson-UTI Energy, relatively high dividend
    Press news
    Test News
    Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
    Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.
    MemeMarket Revolutionizes Meme Coin Market Predictions, A One-Stop Solution For Meme Coin Creators And Enthusiasts
    Bio Protocol (BIO), a DeSci Project, Will Be Innitially Listed on CoinW Exchange
    Saudi Arabia Light Commercial Vehicle Modifiers Market to Hit Valuation of US$ 2,945.24 Million By 2032 | Astute Analytica
    UXUY Officially Launches the UXUY Points ($UP) Reward Program to Boost DEX Trading
    Logoanalist
    Returns European stocks
    Crypto currencies information
    About us Network Partners
    Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos Analist.nlLinksISIN
  • Glossary
    		• MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-xBats
    ©2024 ValueSpectrum. All Rights Reserved
    Developed and maintained by  Velainn logo